Please assess the completion status of the following clinical trial:

Trial Title: Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18~2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~3. Metastatic, locally advanced or recurrent NSCLC, not amenable to curative therapy.~4. Patients should have received at least one platinum-based chemotherapy regimen for recurrent or metastatic disease or have received platinum-based chemotherapy as part of adjuvant or neoadjuvant therapy and experienced progression of disease within 6 months of completing therapy.~5. Patients with tumor genetic alterations such as EGFR, ALK, ROS1 or BRAF V600E alterations for which there is FDA-approved targeted therapy must have been treated with the appropriate targeted inhibitors in prior therapy~6. No limit on number of prior therapies~7. Ability to provide written, informed consent~8. Patients must be on a stable regimen of treatment for their autoimmune condition without need for addition of new medications or escalating doses of preexisting medications in the previous 12 weeks prior to study entry~9. In addition, patients with the following autoimmune diseases must have baseline disease activity scores as follows (please see Appendix A):~   * For rheumatoid arthritis: DAS28 \< 5.1~  * For polymyalgia rheumatica: PMR-AS \< 17~  * For Sjogrens: ESSDAI \< 14~  * For ulcerative colitis: SSCAI \< 5~  * For Crohn's disease: CDAI \< 450~  * For systemic lupus erythroderma: SLEDAI-2K \< 20~  * For multiple sclerosis: EDSS \< 5.5~10. Adequate organ and marrow function as defined by:~    * absolute neutrophil count ≥ 1,500/mcL~   * platelets ≥ 100,000/mcL~   * total bilirubin ≤ 2.5 × institutional upper limit of normal~   * AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal, OR~   * AST(SGOT)/ALT(SGPT ) ≤5 × institutional upper limit of normal if liver metastases are present~   * Creatinine within normal institutional limits OR~   * Creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.~11. Non-pregnant and non-nursing.~12. Women of childbearing potential (WOCBP) must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 5 months after the last dose of study medication. Patients of childbearing potential are those who have not been surgically sterilized or have not been free of menses \> 1 year.~13. Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.~Exclusion Criteria:~1. No chemotherapy or radiotherapy within two weeks of study entry. Prior targeted therapy is allowed as long as at least 5 half-lives have elapsed since last dose.~2. All adverse events (other than alopecia) from prior therapy must be resolved to Grade 1 or less.~3. Patients who are known to be HIV positive are excluded due to the known immunologic alterations associated with the disease. HIV testing is not required.~4. No uncontrolled intercurrent illness such as active infection, or psychiatric illness or social situation that in the judgment of the investigator would limit compliance with study requirements~5. No active interstitial lung disease (ILD) or pneumonitis, or a history of ILD or pneumonitis requiring treatment with corticosteroids~6. No live vaccine within 30 days of start of study treatment~7. No carcinomatous meningitis or untreated CNS metastases~8. No history of significant cardiac disease or presence of an abnormality in electrocardiograms that, in the investigator's opinion, is medically exclusionary or clinically meaningful~9. No other active malignancy~10. No known history of or positivity for active hepatitis B or C. HBV DNA and/or HCV RNA must be undetectable and HBsAg must be negative at the time of screening~11. No active unstable angina and/or congestive heart failure, or myocardial infarction within 6 months prior to protocol participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab: Autoimmune Diseases Cohort 1 (Type: EXPERIMENTAL): Arms determined by autoimmune type. First cohort consists of patients with:~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2.
- Nivolumab: Autoimmune Diseases Cohort 2 (Type: EXPERIMENTAL): Arms determined by autoimmune type. Second cohort consists of patients with:~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues